Figure 2.

Bevacizumab usage within 12 months of FDA approval for colorectal cancer. ^. ^This study followed patients until January, 2006, but data in this figure is shown only until February 2005 as numbers of participants starting any first-line chemotherapy (denominator) within a particular quarter diminishes over time due to the fixed-cohort effect. In the year following approval, the highest percentage of use was seen in July, 2004 (12 of 25, 48%), a month after publication of the pivotal, phase III study which confirmed the drug's efficacy in the first line as a part of combination therapy.

Zafar et al. BMC Cancer 2011 11:354   doi:10.1186/1471-2407-11-354
Download authors' original image